Loargys-Pegzilarginase-Nbln
Loargys (pegzilarginase-nbln) is indicated for the treatment of Arginase 1 Deficiency (ARG1-D), also known as hyperargininemia, in adult and pediatric patients 2 years of age and older, a rare urea cycle disorder characterized by elevated plasma arginine levels and progressive neurological impairment. Loargys functions as an enzyme replacement therapy, reducing toxic arginine accumulation and helping […]
Bysanti-Milsaperidone
Bysanti (milsaperidone) is an FDA-approved atypical antipsychotic indicated for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. As an oral therapy, Bysanti is designed to modulate key neurotransmitter pathways, particularly dopamine and serotonin receptor activity, which play a central role […]
Yuviwel-Navepegritide
Yuviwel (navepegritide) is an FDA-approved C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia who have open epiphyses. Achondroplasia is a rare genetic skeletal disorder characterized by impaired endochondral bone growth due to overactive FGFR3 signaling, resulting in disproportionate short stature and associated […]
Keytruda Qlex-Pembrolizumab And Berahyaluronidase Alfa-Pmph
Keytruda Qlex is an FDA-approved subcutaneous formulation of Keytruda developed by Merck & Co. It contains the active immunotherapy molecule pembrolizumab, a PD-1 immune checkpoint inhibitor, combined with berahyaluronidase alfa, an enzyme that enables rapid subcutaneous delivery. Unlike the traditional intravenous (IV) infusion of Keytruda administered over 30 minutes, Keytruda Qlex is given as a […]
Adquey-Difamilast
Adquey (Difamilast) is a topical phosphodiesterase-4 (PDE4) inhibitor developed for the treatment of atopic dermatitis (AD) in adult and pediatric patients aged 2 years and older. Adquey delivers targeted anti-inflammatory and antipruritic effects with a rapid onset of action, resulting in significant clinical improvement within the first week of treatment. Difamilast works by selectively inhibiting […]
Nereus-Tradipitant
Nereus (tradipitant) is a newly FDA‑approved oral neurokinin‑1 (NK‑1) receptor antagonist indicated for the prevention of vomiting induced by motion sickness in adults, representing the first new pharmacologic option for this condition in over 40 years; it works by selectively blocking substance P–mediated activation of NK‑1 receptors in the brain to reduce motion‑induced vomiting, and […]
Zycubo-Copper Histidinate
Zycubo (copper histidinate) is a bioavailable copper replacement therapy approved by the U.S. FDA in January 2026 as the first and only treatment for Menkes disease in pediatric patients. It is a rare X‑linked genetic disorder in which the body cannot absorb or transport copper properly, leading to severe neurodegeneration and early mortality. It is administered […]
Yartemlea-Narsoplimab-Wuug
Yartemlea is a fully human monoclonal antibody that selectively inhibits mannan-binding lectin–associated serine protease-2 (MASP-2), a key enzyme in the lectin pathway of the complement system. It is approved for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and pediatric patients aged two years and older. By blocking MASP-2, Yartemlea prevents […]
Nuzolvence-Zoliflodacin
Nuzolvence (zoliflodacin) is a first-in-class, oral antibacterial agent indicated for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents aged 12 years and older who meet weight requirements. Zoliflodacin belongs to a novel class of spiropyrimidinetrione antibiotics and inhibits bacterial type II topoisomerase enzymes, which are essential for DNA replication in Neisseria gonorrhoeae. This […]
Cardamyst-Etripamil
Cardamyst (etripamil) is a prescription intranasal therapy indicated for the acute conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is a rapid-acting calcium channel blocker that slows conduction through the atrioventricular (AV) node, helping terminate abnormal cardiac electrical activity responsible for PSVT. Designed for self-administration at symptom onset, Cardamyst provides a […]
